A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 866-872

  Owonikoko, Taofeek K ^a   Behera, Madhusmita ^a   Chen, Zhengjia ^a   Bhimani, Chandar ^a   Curran, Walter J ^a   Khuri, Fadlo R ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Refractory; Resistant; Sensitive; Small cell lung cancer

Indexed keywords

AMRUBICIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LURTOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PICOPLATIN; TOPOTECAN; TRIPLATIN TETRANITRATE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; GENETIC HETEROGENEITY; HUMAN; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 84862142866     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824c7f4b     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Owonikoko TK, Ragin CC, Belani CP,. et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-5577.
3. Owonikoko TK Ramalingam S. Small cell lung cancer in elderly patients: a review. J Natl Compr Canc Netw 2008;6:333-344.
4. Lara PN Jr, Natale R, Crowley J,. et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
5. Clark R Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park, NY) 1998;12:647-58; discussion 661.
6. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;CD001990.
7. Ardizzoni A, Boni L, Tiseo M,. et al.; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
8. Owonikoko T Ramalingam S. Minimal progress, potential promise in small-cell lung cancer. Oncology (Williston Park, NY) 2008;22:1495-1496.
9. Hanna N, Bunn PA, Jr., Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
10. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
11. von Pawel J, Schiller JH, Shepherd FA,. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
12. O'Brien ME, Ciuleanu TE, Tsekov H,. et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447.
13. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
14. Cheng S, Evans WK, Stys-Norman D, Shepherd FA; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: A systematic review and practice guideline. J Thorac Oncol 2007;2:348-354.
15. Treat J, Huang CH, Lane SR, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004;9:173-181.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
17. Eckardt JR, Bentsion DL, Lipatov ON,. et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-2051.
18. Jalal S, Waterhouse D, Edelman MJ,. et al. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol 2009;4:1420-1424.
19. Grønberg BH, Bremnes RM, Aasebø U,. et al.; Norwegian Lung Cancer Study Group. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2009;63:88-93.
20. Rocha-Lima CM, Herndon JE 2nd, Lee ME,. et al.; Cancer and Leukemia Group B. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 2007;18:331-337.
21. Ardizzoni A, Manegold C, Debruyne C,. et al.; Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003;9:143-150.
22. Naka N, Kawahara M, Okishio K,. et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323.
23. Sculier JP, Lafitte JJ, Lecomte J,. et al.; European lung cancer working party. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002;13:1454-1459.
24. Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119-126.
25. Sonpavde G, Ansari R, Walker P,. et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 2000;23:68-70.
26. Ardizzoni A, Hansen H, Dombernowsky P,. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.
27. Schuette W, Nagel S, Juergens S,. et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005;7:133-137.
28. Ichiki M, Gohara R, Rikimaru T,. et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy 2003;49:200-205.
29. Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs 2006;17:697-704.
30. Dómine M, Larriba JLG, Morales S, et al: Gemcitabine and Paclitaxel as Second Line Treatment in Small Cell Lung Cancer (SCLC). A Multicentric Phase II Study. Proc Am Soc Clin Oncol 2001;20:abstr 1263.
31. Dongiovanni V, Buffoni L, Berruti A,. et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2006;58: 203-209.
32. Hoang T, Kim K, Jaslowski A,. et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003;42:97-102.
33. Hainsworth JD, Burris HA 3rd, Erland JB,. et al.; Minnie Pearl Cancer Research Network. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2003;21:193-199.
34. Sessa C, Wanders J, Roelvink M, et al: Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 2000;11:207-210, 2000
35. Huber RM, Reck M, Gosse H,. et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 2006;27:1183-1189.
36. von Pawel J, Jotte R, Spigel DR, et al: Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC) J Thorac Oncol 2011;6:S274; Abstract O
37. Vigano MG, Cavina R, Novello S, et al: Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). J Clin Oncol2011; 29 (suppl; abstr 7077) 29:suppl; abstr 7077.
38. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 2011;61:91-112.
39. Chute JP, Kelley MJ, Venzon D, Williams J, Roberts A, Johnson BE. Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. Chest 1996;110:165-171.
40. Agra Y, Pelayo M, Sacristan M, Sacristán A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003;CD001990.
41. Ettinger DS, Berkey BA, Abrams RA,. et al.; Radiation Therapy Oncology Group 9609. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 2005;23:4991-4998.
42. Greco FA, Thompson DS, Morrissey LH,. et al. Paclitaxel/carboplatin/ etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Oncologist 2005;10:728-733.
43. Niell HB, Herndon JE 2nd, Miller AA,. et al.; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759.
44. Froeschl S, Nicholas G, Gallant V, Laurie SA. Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer. J Thorac Oncol 2008;3:163-169.
45. Kim YH, Goto K, Yoh K,. et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 2008;113:2518-2523.
46. Lilenbaum RC, Huber RM, Treat J,. et al. Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. Clin Lung Cancer 2006;8:130-134.
47. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
48. Chute JP, Venzon DJ, Hankins L,. et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 1997;72:901-912.